Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T63206
|
|||||
Target Name |
Integrin alpha-5/beta-1 (ITGA5/B1)
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 2 Target-related Diseases | + | ||||
1 | Autoimmune liver disease [ICD-11: DB96] | |||||
2 | Idiopathic interstitial pneumonitis [ICD-11: CB03] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | PLN-74809 | Drug Info | Phase 2 | Idiopathic pulmonary fibrosis | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 1 Inhibitor drugs | + | ||||
1 | PLN-74809 | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Dual inhibition of alpha(v)beta(6) and alpha(v)beta(1) reduces fibrogenesis in lung tissue explants from patients with IPF. Respir Res. 2021 Oct 19;22(1):265. | |||||
REF 2 | ClinicalTrials.gov (NCT05621252) A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Evaluation of PLN-74809 on Type 1 Collagen Deposition Using 68Ga-CBP8 PET/MRI Imaging in Participants With Idiopathic Pulmonary Fibrosis (IPF). U.S.National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.